Statin Therapy Guidelines for Adults with Low to Moderate ASCVD Risk

Risk Stratification and Treatment Thresholds

The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend statin therapy for adults aged 40-75 years without diabetes when 10-year ASCVD risk is ≥7.5% after a clinician-patient risk discussion 2, 1
The US Preventive Services Task Force (USPSTF) guidelines set an even higher threshold, recommending statins at ≥10% 10-year risk 1
Adults with <5% risk generally do not require statin therapy unless other indications are present, according to the ACC/AHA guidelines 1

Evaluate for risk-enhancing factors that might justify statin therapy even at low calculated risk, such as family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, metabolic syndrome, chronic kidney disease, chronic inflammatory disorders, history of preeclampsia or premature menopause, high-risk ethnicity, or persistent triglycerides ≥175 mg/dL 1, 2

Coronary artery calcium (CAC) scoring can guide decision-making if uncertainty exists or if the patient has borderline risk factors, with CAC = 0 strongly supporting withholding statin therapy, CAC 1-99 possibly favoring statin therapy, and CAC ≥100 or ≥75th percentile indicating statin therapy is necessary regardless of calculated risk 1

Aggressively emphasize lifestyle modifications, including heart-healthy diet, regular physical activity, weight management, smoking cessation, and blood pressure control, as the foundation of ASCVD prevention 2, 1
Screen for risk-enhancing factors that might change the recommendation for statin therapy 1
Consider CAC scoring if the patient has multiple borderline risk factors or strong family history 1

Do not prescribe statins based on age alone without considering complete risk profile 1
Do not ignore the importance of lifestyle modifications even when deferring statin therapy 1
Do not overlook LDL-C levels, as statin therapy is indicated regardless of calculated risk if LDL-C is ≥190 mg/dL 2, 1
Do not fail to conduct a clinician-patient risk discussion if considering statin therapy, as this is mandatory per guidelines 2, 1

The ACC/AHA guidelines provide Class I (strong) evidence for statin therapy at ≥7.5% risk, but explicitly state that adults with <5% risk generally do not require statin therapy 2, 1
The evidence supporting statin therapy comes from randomized controlled trials that predominantly enrolled patients at higher baseline risk, resulting in a minimal absolute benefit at 3% risk (approximately 0.6-0.9% absolute risk reduction over 10 years) 2, 1
The number needed to treat to prevent one ASCVD event at 7.5% risk is already 57-67, and would be substantially higher at 3% risk, making the benefit-to-harm ratio unfavorable 1